Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.49 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.46 |
| ▸ | CDC42BPB | Q9Y5S2 | 4/20 | 0.46 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 6/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.45 |
| ▸ | PIM1 | P11309 | 4/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1469328 | 1.00 | AAK1 (0.49) | AAK1MAP4K1ROCK2ROCK1CDC42BPB | |
| Hydrochloric Acid SCHEMBL1468227 | 0.99 | AAK1 (0.49) | AAK1MAP4K1ROCK2ROCK1CDC42BPB | |
| Hydrochloric Acid SCHEMBL1468229 | 0.99 | AAK1 (0.49) | AAK1MAP4K1ROCK2ROCK1CDC42BPB | |
| SCHEMBL10222699 | 0.93 | AAK1 (0.51) | AAK1MAP4K1ROCK2ROCK1CDC42BPB | |
| SCHEMBL14695584 | 0.91 | AAK1 (0.47) | AAK1MAP4K1ROCK2ROCK1CDC42BPB | |
| SCHEMBL1468772 | 0.91 | AAK1 (0.47) | AAK1MAP4K1ROCK2ROCK1CDC42BPB | |
| SCHEMBL1468665 | 0.89 | PIM2 (0.47) | AAK1MAP4K1ROCK2ROCK1CDC42BPB | |
| SCHEMBL1468662 | 0.89 | PIM2 (0.47) | AAK1MAP4K1ROCK2ROCK1CDC42BPB | |
| SCHEMBL1468272 | 0.89 | AAK1 (0.48) | AAK1ROCK2ROCK1CDC42BPBPIM1 | |
| Hydrochloric Acid SCHEMBL1467780 | 0.89 | PIM2 (0.46) | AAK1MAP4K1ROCK2ROCK1CDC42BPB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969727-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20160368916-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-9365568-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2990407-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20150322061-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2015-11-12 | — | — | US | disclosed |
| EP-2307409-B1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8758830-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140100369-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8545897-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130045286-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-8178131-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110070317-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368916-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | AAK1 438/4885MAP4K1 82/4885ROCK2 1602/4885 |
| US-20140100369-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | AAK1 438/4885MAP4K1 82/4885ROCK2 1602/4885 |
| US-20110070317-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | AAK1 453/4885MAP4K1 75/4885ROCK2 1355/4885 |
| US-20150322061-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | AAK1 438/4885MAP4K1 82/4885ROCK2 1602/4885 |
| US-20130045286-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | AAK1 438/4885MAP4K1 82/4885ROCK2 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.